Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Foralumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Foralumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Foralumab. |
| Estrone | Estrone may increase the thrombogenic activities of Foralumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Foralumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Foralumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Foralumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Foralumab. |
| Estriol | Estriol may increase the thrombogenic activities of Foralumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Foralumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Foralumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Foralumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Foralumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Foralumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Foralumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Foralumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Foralumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Foralumab. |
| Equol | Equol may increase the thrombogenic activities of Foralumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Foralumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Foralumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Foralumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Foralumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Foralumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Foralumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Foralumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Foralumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Foralumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Foralumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Foralumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Foralumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Foralumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Foralumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Foralumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Foralumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Foralumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Foralumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Foralumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Foralumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Foralumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Foralumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Foralumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Foralumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Foralumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Foralumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Foralumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Foralumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Foralumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Foralumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Foralumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Foralumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Foralumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Foralumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Foralumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Foralumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Foralumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Foralumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Foralumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Foralumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Foralumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Foralumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Foralumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Foralumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Foralumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Foralumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Foralumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Foralumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Foralumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Foralumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Foralumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Foralumab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Foralumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Foralumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Foralumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Foralumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Foralumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Foralumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Foralumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Foralumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Foralumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Foralumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Foralumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Foralumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Foralumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Foralumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Foralumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Foralumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Foralumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Foralumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Foralumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Foralumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Foralumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Foralumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Foralumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Foralumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Foralumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Foralumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Foralumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Foralumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Foralumab. |